Trial Profile
A Randomized and Open-label Dose-finding, Ph. 2, Efficacy, Safety, and Pharmacokinetic Study of Once-per-cycle Prophylactic Injections of ANF-RHO Versus Pegfilgrastim (Neulasta) in Non-metastatic Breast Cancer Patients at High-risk of Chemotherapy-induced Neutropenia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 May 2019
Price :
$35
*
At a glance
- Drugs Pegfilgrastim ANF (Primary) ; Pegfilgrastim
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Prolong Pharmaceuticals
- 08 Feb 2019 Status changed from recruiting to discontinued.
- 30 Jan 2017 New trial record